ADAR1 Capital Management »

Cytokinetics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Cytokinetics (CYTK) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Cytokinetics

Tip: Access up to 7 years of quarterly data

All positions including Cytokinetics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cytokinetics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $14M 169k 83.49

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Cytokinetics

Vanguard Group
Wellington Management Company
Caption Management
T. Rowe Price Associates
Henderson Group
Boxer Capital
Citadel Advisors
Partner Fund Management
Logos Global Management
Lord, Abbett & Co
Millennium Management
Artal Group
Barclays
Gts Securities
Goldman Sachs Group

View all funds holding Cytokinetics